Chronic Lymphocytic Leukemia Clinical Trial
Evaluate the Efficacy and Safety of TGR-1202 in Patients With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy
Summary
This is a Phase 2, open-label, study of TGR-1202, a PI3K delta inhibitor, administered as a single agent in Chronic Lymphocytic Leukemia (leukemia-cll/" >CLL) patients who are intolerant to prior BTK inhibitors (ibrutinib, other) or prior PI3K delta inhibitors (idelalisib, other)
Eligibility Criteria
Inclusion Criteria:
Confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL)
Discontinuation on prior BTK inhibitor or PI3K delta inhibitor due to adverse events within prior 9 months
Presence of measurable disease
Exclusion Criteria:
Progression on prior BTK or PI3K delta inhibitor
Prior treatment with TGR-1202
Richter's transformation or CLL transformation to aggressive lymphoma
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 15 Locations for this study
Huntsville Alabama, 35805, United States
Washington District of Columbia, 20007, United States
Fort Myers Florida, 33916, United States
Saint Petersburg Florida, 33705, United States
Kansas City Missouri, 64132, United States
Lebanon New Hampshire, 03756, United States
Hackensack New Jersey, 07601, United States
New Hyde Park New York, 11042, United States
New York New York, 10032, United States
Rochester New York, 14642, United States
Durham North Carolina, 27710, United States
Hershey Pennsylvania, 17033, United States
Philadelphia Pennsylvania, 19146, United States
Nashville Tennessee, 37203, United States
Seattle Washington, 98104, United States
How clear is this clinincal trial information?
